<DOC>
	<DOCNO>NCT01466660</DOCNO>
	<brief_summary>This randomise , open-label , phase IIb trial afatinib compare gefitinib first-line treatment set patient epidermal growth factor receptor mutation positive advanced adenocarcinoma lung .</brief_summary>
	<brief_title>LUX-Lung 7 : A Phase IIb Trial Afatinib ( BIBW2992 ) Versus Gefitinib Treatment 1st Line EGFR Mutation Positive Adenocarcinoma Lung</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Inclusion criterion : 1 . Pathologically confirm diagnosis Stage IIIB / IV adenocarcinoma lung . 2 . Documented activate epidermal growth factor receptor mutation ( Del19 and/or L858R ) tumour tissue . 3 . At least one measurable lesion accord response evaluation criterion solid tumour version 1.1 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 5 . Age &gt; = 18 year . 6 . Adequate organ function define follow criterion : Serum aspartate transaminase ( AST ) serum alanine transaminase ( ALT ) = &lt; 3 x upper limit normal ( ULN ) , AST ALT = &lt; 5 x ULN liver function abnormality due underlie malignancy Total serum bilirubin = &lt; 1.5 x ULN Absolute neutrophil count ( ANC ) &gt; =1.5 x 109/L Creatinine clearance &gt; 45ml / min Platelets &gt; = 75 x 109/L Exclusion criterion : 1 . Prior systemic chemotherapy stage IIIB IV nonsmall cell lung cancer . Neo/adjuvant chemotherapy , chemoradiation radiotherapy permit least 12 month elapse prior disease progression . 2 . Prior treatment epidermal growth factor receptor target small molecule antibody . 3 . Major surgery within 4 week study randomisation . 4 . Active brain metastasis 5 . Meningeal carcinomatosis . 6 . Previous concomitant malignancy site , except effectively treat nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ effectively treat malignancy remission 3 year consider cured opinion investigator . 7 . Known preexist interstitial lung disease . 8 . Clinically relevant cardiovascular abnormality judge investigator . 9 . Cardiac leave ventricular function rest ejection fraction less institutional low limit normal . 10 . Women childbearing potential ( WOCBP ) men able father child , unwilling abstinent use adequate contraception prior study entry , duration study participation least 2 month treatment end . 11 . Pregnancy breastfeed . 12 . Active hepatitis and/or know HIV carrier 13 . Any prohibited concomitant medication therapy afatinib gefitinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>